Christopher Burke, MD
Psychiatry · Smithtown, NYNPI 1427099621
Payments from drug & device makers
Across 91 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$492
- AbbVie$455
- Sunovion Pharmaceuticals Inc.$173
- Vanda Pharmaceuticals Inc.$109
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$80
- Neurocrine Biosciences, Inc.$42
- plus $178 from 8 others
What the payments were for
- Food & beverage$1,521100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 29 | $492 |
| AbbVie(2 entities) | 28 | $455 |
| Sunovion Pharmaceuticals Inc. | 14 | $173 |
| Vanda Pharmaceuticals Inc. | 4 | $109 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $80 |
| Neurocrine Biosciences, Inc. | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Bausch Health US, LLC | 2 | $30 |
| Shire North American Group Inc | 1 | $24 |
| Neuronetics, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $15 |
How this compares
$1,528 in reported general payments places this provider in the 80th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LamictalLamotrigine | 15 | $10,813 |
| Lurasidone Hcl | 13 | $4,564 |
| Aripiprazole | 16 | $2,729 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 36 | $1,512 |
| Bupropion XlBupropion Hcl | 65 | $960 |
| Duloxetine Hcl | 12 | $925 |
| Clonazepam | 70 | $450 |
| Mirtazapine | 44 | $440 |
| Alprazolam | 39 | $417 |
| Zolpidem Tartrate | 47 | $388 |
| Lorazepam | 108 | $355 |
| Methylphenidate Hcl | 20 | $277 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $248 |
| Quetiapine Fumarate | 31 | $222 |
| Paroxetine Hcl | 11 | $217 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Smithtown
- Elyssa BarronWhite Plains$12.8M
- Mark DibuonoStaten Island$11.9M
- Ronald BrennerHempstead$11.5M
- Anton PorsteinssonRochester$7.6M
- Michael LiebowitzNew York$7.1M
- Leslie CitromePomona$5.7M
- John KaneGlen Oaks$4M
- Inna Yuryev-GolgerBrooklyn$3M
- Subhdeep VirkBuffalo$3M
- Paul EderNew York$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.